Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia

NCT00001197 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Anemia

Interventions

DRUG: Hydroxyurea

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)